Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer

Journal of Clinical Oncology

Volumn 21, Issue 13, 2003, Pages 2492-2499

  Johnston, Stephen R D ^a   Hickish, Tamas ^a   Ellis, Paul ^a   Houston, Stephen ^a   Kelland, Lloyd ^a   Dowsett, Mitch ^a   Salter, Janine ^a   Michiels, Bart ^a   Perez Ruixo, Juan Jose ^a   Palmer, Peter ^a   Howes, Angela ^a  

^a GUY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

TIPIFARNIB; QUINOLONE DERIVATIVE;

ADVANCED CANCER; ARTICLE; BREAST CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT RESPONSE; ADULT; AGED; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; DISEASE COURSE; DOSE RESPONSE; DRUG ADMINISTRATION; FEMALE; METASTASIS; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PATHOLOGY; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; NEUTROPENIA; QUINOLONES; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0038352147     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.10.064     Document Type: Article

References (33)

1. Slamon DJ, Leyland-Jones B, Shal S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001
2. McCormack F: Activators and effectors of ras p21 proteins. Curr Opin Genet Dev 4:71-76, 1994
3. Clark GJ, Der CJ: Ras proto-oncogene activation in human malignancy, in Markers CT, Garret T, Sell S (eds): Cellular Cancer. Totowa, NJ, Humana Press, 1995, pp 17-52
4. Clark GJ, Der CJ: Aberrant function of the Ras signal transduction pathway in human breast cancer. Breast Cancer Res Treat 35:133-144, 1995
5. Kato K, Cox AD, Hisaka MM, et al: Isoprenoid addition to ras protein is the critical modification for its membrane association and transforming activity. Proc Natl Acad Sci 89:6403-6407, 1992
6. Johnston SRD: Farnesyl transferase inhibitors: A novel targeted therapy for cancer. Lancet Oncol 2:18-26, 2001
7. Rowinsky EK, Windle JJ, VonHoff DD: Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development. J Clin Oncol 17:3631-3652, 1999
8. End DW, Smets G, Todd AV, et al: Characterisation of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res 61:131-137, 2001
9. Kelland LR, Smith V, Valenti M, et al: Preclinical antitumor activity and pharmacodynamic studies with the farnesyl protein transferase inhibitor R115777 in human breast cancer. Clin Cancer Res 7:3544-3550, 2001
10. Zujewski J, Horak ID, Bol CJ, et al: Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer. J Clin Oncol 18:927-941, 2000
11. Hudes GR, Schol J, Baab J, et al: Phase I clinical and pharmacokinetic trial of the farnesylytransferase inhibitor R115777 on a 21-day dosing schedule. Proc Am Soc Clin Oncol 18:A601, 1999
12. Crul M, de Klerk GJ, Swart M, et al: Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer. J Clin Oncol 20:2726-2735, 2002
13. Perez-Ruixo JJ, Cowan KH, Weiner L, et al: Population pharmacokinetics of Zamestra using data from phase I trials. Presented at K meeting of Population Approach Group in Europe, 2002 (abstr 21). http://userpage.fu-berlin.de/~page/
14. Mandema JW, Stanski DR. Population pharmacodynamic model for keterolac analgesia. Clin Pharmacol Ther 60:619-635, 1996
15. Sheiner LB, Deal SL, Dunne A: Analysis of nonrandomly censored ordered categorical longitudinal data from analgesic trials. J Am Slat Assoc 92:1235-1255, 1997
16. Newby J, Johnston SRD, Smith IE, et al: Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer. Clin Cancer Res 3:1643-1651, 1997
17. Simon R: Optimal two-stage design for phase II clinical trials. Control Clin Trials 10:1-10, 1989
18. Eskens F, Awada A, Cutler DL, et al: Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily in patients with advanced solid tumors. J Clin Oncol 19:1167-1175, 2001
19. Adjei AA, Erlichman C, Davis JD, et al: A phase I trial of the farnesyl transferase inhibitor SCH66336: Evidence for biological and clinical activity. Cancer Res 60:1871-1877, 2000
20. Ryan DP, Eder JP, Supko JG, et al: Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 in patients with advanced solid tumors. Proc Am Soc Clin Oncol 19:185a, 2000 (abstr 720)
21. Britten CD, Rowinsky EK, Soignet S, et al: A phase I and pharmacological study of the farnesyl protein transferase inhibitor L-778,123 in patients with solid malignancies. Clin Cancer Res 7:3894-3903, 2001
22. Cunningham D, De Gramont A, Scheithauer W, et al: Randomised double-blind placebo-controlled trial of the farnesyltransferase inhibitor R115777 (Zarnestra) in advanced colorectal cancer. Proc Am Soc Clin Oncol 21:126a, 2002 (abstr 502)
23. Gibbs JB, Oliff A: The potential of farnesyltransferase inhibitors as cancer chemotherapeutics. Annu Rev Pharmacol Toxicol 37:143-166, 1997
24. Sepp-Lorenzino L, Ma Z, Rands E, et al: A peptidomimetic inhibitor of farnesyl protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines. Cancer Res 55:5302-5309, 1995
25. Du W, Lebowitz PF, Prendergast GC: Cell growth inhibition by farnesyl transferase inhibitors is mediated by gain of geranylgeranylated RhoB. Mol Cell Biol 19:1831-1840, 1999
26. Moasser MM, Sepp-Lorenzino L, Khol NE, et al: Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones. Proc Natl Acad Sci U S A 95:1369-1374, 1998
27. Gee JMW, Robertson JFR, Ellis IO, et al: Phosphorylation of erk 1/2 mitogen activated protein kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancer. Int J Cancer 95:247-254, 2001
28. McClelland RA, Barrow D, Madden T-A, et al: Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182,780 (Faslodex). Endocrinology 142:2776-2788, 2001
29. Jeng M-U, Yue W, Eischeid A, et al: Role of MAP kinase in the enhanced cell proliferation of long-term estrogen deprived human breast cancer cells. Breast Cancer Res Treat 62:167-175, 2000
30. Johnston SRD, Head JE, Valenti MR, et al: Endocrine therapy combined with the farnesyl transferase inhibitor (FTI) Rl 15777 produces enhanced tumour growth inhibition in hormone-sensitive MCF-7 human breast cancer xenografts in-vivo. Breast Cancer Res Treat 76:S71, 2002 (abstr 245)
31. Lee FYF, Arico M, Camuso A, et al: The FT inhibitor BMS-214662 selectively targets the non-proliferating cell subpopulation in solid tumors: Implications for a synergistic therapeutic strategy. Proc Am Assoc Cancer Res 42:260, 2001 (abstr 1402)
32. Du W, Liu A, Prendergast GC: Activation of the PI3′K-AKT pathway masks the pro-apoptotic effects of farnesyltransferase inhibitors. Cancer Res 59:4208-4212, 1999
33. Lee AV, Jackson JG, Gooch JL, et al: Enhancement of insulin-like growth factor signaling in human breast cancer Estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo. Mol Endocrinol 13:787-796, 1999